Zin W Myint

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Zin W Myint sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Zin W Myint: 3 sponsored US clinical trials, 1 recruiting.

Zin W Myint sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.

Upper-quartile sponsor footprint

Zin W Myint sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Zin W Myint pipeline

1 recruiting of 3 indexed (33% open); 1 completed (33%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (2 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Zin W Myint: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Zin W Myint sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share Zin W Myint10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Zin W Myint sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Zin W Myint sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Zin W Myint page

3 registered trials is a research-attention snapshot, not an endorsement of Zin W Myint or any single study.

  • 1 of Zin W Myint's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Zin W Myint studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Zin W Myint pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.